DoorDash (DASH) is joining the fight against the coronavirus pandemic, announcing plans to team up with two health providers to offer same-day delivery of COVID-19 test kits with quick turnaround times.
The move comes as the country's mass vaccination efforts gather steam, but the gradual relaxation of restrictions has stoked concerns about the potential for rising infections.
"COVID-19 testing will continue to play a critical role as businesses and schools begin to re-open across the U.S.," a spokesperson told Yahoo Finance.
The representative added that the partnership offers "even more convenience to customers as they eliminate the need to make a trip to a testing facility, or wait in long lines at the pharmacy or grocery store....expediting the testing process and offering a reliable experience from the comfort of home."
The new offering will allow customers to access two FDA-approved COVID-19 test collection kits on-demand from DoorDash's DashMart locations across the nation, the spokesperson said. The Vault Health COVID-19 Saliva Test Kit, which retails for $119 and offers a 24-hour turn around, includes a prepaid overnight shipping envelope to be delivered to Vault's partner laboratories in New Jersey and Minnesota.
Everlywell COVID-19 test kits cost $109 and use a nasal swab. It includes a prepaid shipping label for customers to ship overnight to a certified lab. Results are also available within 24 hours.
The rapid at-home test kit, and DoorDash's involvement, represent "a significant step forward for public health," according to Dr. Marisa Cruz, Head of Clinical Affairs at Everlywell, who is also a former FDA adviser.
The ability to "get a kit delivered to your door in hours, quickly collect a sample and drop your kit in the mail, and then receive an accurate COVID-19 diagnosis and speak to a physician about next steps in as little as 24 hours later," Cruz said.
However, it's not entirely clear whether at-home testing is fully covered by insurance. The kits "may be reimbursable through insurance," according to Everlywell, which says it is "not a healthcare provider nor a laboratory and therefore cannot bill your health insurance directly."
Meanwhile, Vault notes that it is considered "out-of-network with all health insurance plans and providers and cannot submit a claim for you."
Each purchase does come with an itemized receipt that consumers can submit to their insurer.
DoorDash has been making a concerted push to infiltrate health care. Last year, the company announced that over-the-counter health and wellness products from Walgreens (WBA) were now available on its app. And in October, the company announced it teamed with Sam’s Club Pharmacy (WMT) to power same-day prescription delivery.
On Monday, DoorDash closed at $135.91 per a share. Meanwhile, shares are down nearly 23% from its debut on the New York Stock Exchange back in December.
Brooke DiPalma is a producer and reporter for Yahoo Finance. Follow her on Twitter at @BrookeDiPalma or email her at firstname.lastname@example.org.